Panel Discussion: Addressing Safety Concerns Associated with Viral & Nonviral Neurological Gene Therapies
Time: 5:00 pm
day: Conference Day One
Details:
- Considering safety and immunogenicity challenges associated with delivering viral gene therapies to the CNS
- Looking in to dose related toxicity when using a higher dose to ensure high efficacy
- Debating whether nonviral vectors pose more or less of a safety concern when delivering to the CNS than viral vectors
